Short- and long-term T cell and antibody responses following dexamethasone treatment in COVID-19
BACKGROUNDAfter its introduction as standard-of-care for severe COVID-19, dexamethasone has been administered to a large number of patients globally. Detailed knowledge of its impact on the cellular and humoral immune response to SARS-CoV-2 remains scarce.METHODSWe included immunocompetent individuals with (a) mild COVID-19, (b) severe COVID-19 before introduction of dexamethasone treatment, and (c) severe COVID-19 infection treated with dexamethasone from prospective observational cohort studies at Charité-Universitätsmedizin Berlin, Germany. We analyzed SARS-CoV-2 spike-reactive T cells, spike-specific IgG titers, and serum neutralizing activity against B.1.1.7 and B.1.617.2 in samples ranging from 2 weeks to 6 months after infection. We also analyzed BA.2 neutralization in sera after booster immunization.RESULTSPatients with severe COVID-19 and dexamethasone treatment had lower T cell and antibody responses to SARS-CoV-2 compared with patients without dexamethasone treatment in the early phase of disease, which converged in both groups before 6 months after infection and also after immunization. Patients with mild COVID-19 had comparatively lower T cell and antibody responses than patients with severe disease, including a lower response to booster immunization during convalescence.CONCLUSIONDexamethasone treatment was associated with a short-term reduction in T cell and antibody responses in severe COVID-19 when compared with the nontreated group, but this difference evened out 6 months after infection. We confirm higher cellular and humoral immune responses in patients after severe versus mild COVID-19 and the concept of improved hybrid immunity upon immunization.FUNDINGBerlin Institute of Health, German Federal Ministry of Education, and German Federal Institute for Drugs and Medical Devices.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
JCI insight - 8(2023), 8 vom: 24. Apr. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Thibeault, Charlotte [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
7S5I7G3JQL |
|---|
| Anmerkungen: |
Date Completed 25.04.2023 Date Revised 08.06.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1172/jci.insight.166711 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM353872598 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM353872598 | ||
| 003 | DE-627 | ||
| 005 | 20231226061016.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1172/jci.insight.166711 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1179.xml |
| 035 | |a (DE-627)NLM353872598 | ||
| 035 | |a (NLM)36881474 | ||
| 035 | |a (PII)e166711 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Thibeault, Charlotte |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Short- and long-term T cell and antibody responses following dexamethasone treatment in COVID-19 |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.04.2023 | ||
| 500 | |a Date Revised 08.06.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUNDAfter its introduction as standard-of-care for severe COVID-19, dexamethasone has been administered to a large number of patients globally. Detailed knowledge of its impact on the cellular and humoral immune response to SARS-CoV-2 remains scarce.METHODSWe included immunocompetent individuals with (a) mild COVID-19, (b) severe COVID-19 before introduction of dexamethasone treatment, and (c) severe COVID-19 infection treated with dexamethasone from prospective observational cohort studies at Charité-Universitätsmedizin Berlin, Germany. We analyzed SARS-CoV-2 spike-reactive T cells, spike-specific IgG titers, and serum neutralizing activity against B.1.1.7 and B.1.617.2 in samples ranging from 2 weeks to 6 months after infection. We also analyzed BA.2 neutralization in sera after booster immunization.RESULTSPatients with severe COVID-19 and dexamethasone treatment had lower T cell and antibody responses to SARS-CoV-2 compared with patients without dexamethasone treatment in the early phase of disease, which converged in both groups before 6 months after infection and also after immunization. Patients with mild COVID-19 had comparatively lower T cell and antibody responses than patients with severe disease, including a lower response to booster immunization during convalescence.CONCLUSIONDexamethasone treatment was associated with a short-term reduction in T cell and antibody responses in severe COVID-19 when compared with the nontreated group, but this difference evened out 6 months after infection. We confirm higher cellular and humoral immune responses in patients after severe versus mild COVID-19 and the concept of improved hybrid immunity upon immunization.FUNDINGBerlin Institute of Health, German Federal Ministry of Education, and German Federal Institute for Drugs and Medical Devices | ||
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Adaptive immunity | |
| 650 | 4 | |a Immunology | |
| 650 | 4 | |a Immunotherapy | |
| 650 | 4 | |a Infectious disease | |
| 650 | 4 | |a T cells | |
| 650 | 7 | |a Dexamethasone |2 NLM | |
| 650 | 7 | |a 7S5I7G3JQL |2 NLM | |
| 700 | 1 | |a Bardtke, Lara |e verfasserin |4 aut | |
| 700 | 1 | |a Vanshylla, Kanika |e verfasserin |4 aut | |
| 700 | 1 | |a di Cristanziano, Veronica |e verfasserin |4 aut | |
| 700 | 1 | |a Eberhardt, Kirsten A |e verfasserin |4 aut | |
| 700 | 1 | |a Stubbemann, Paula |e verfasserin |4 aut | |
| 700 | 1 | |a Hillus, David |e verfasserin |4 aut | |
| 700 | 1 | |a Tober-Lau, Pinkus |e verfasserin |4 aut | |
| 700 | 1 | |a Mukherjee, Parnika |e verfasserin |4 aut | |
| 700 | 1 | |a Münn, Friederike |e verfasserin |4 aut | |
| 700 | 1 | |a Lippert, Lena J |e verfasserin |4 aut | |
| 700 | 1 | |a Helbig, Elisa T |e verfasserin |4 aut | |
| 700 | 1 | |a Lingscheid, Tilman |e verfasserin |4 aut | |
| 700 | 1 | |a Steinbeis, Fridolin |e verfasserin |4 aut | |
| 700 | 1 | |a Mittermaier, Mirja |e verfasserin |4 aut | |
| 700 | 1 | |a Witzenrath, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Zoller, Thomas |e verfasserin |4 aut | |
| 700 | 0 | |a Pa-COVID study group |e verfasserin |4 aut | |
| 700 | 1 | |a Klein, Florian |e verfasserin |4 aut | |
| 700 | 1 | |a Sander, Leif E |e verfasserin |4 aut | |
| 700 | 1 | |a Kurth, Florian |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t JCI insight |d 2016 |g 8(2023), 8 vom: 24. Apr. |w (DE-627)NLM257703918 |x 2379-3708 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2023 |g number:8 |g day:24 |g month:04 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1172/jci.insight.166711 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2023 |e 8 |b 24 |c 04 | ||